---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-338008"
form_type: "8-K"
ticker: "ALEC"
cik: "0001653087"
company_name: "Alector, Inc."
filed_at: "2026-08-06T20:10:49+00:00"
generated_at: "2026-08-06T20:14:10.732127+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Alector Q2 net loss narrows to $23M; cash runway through 2027; AL137 IND targeted Q1 2027

## Summary
- Net loss of $23.0M ($0.21/share) vs $30.5M ($0.30/share) in Q2 2025; revenue $3.3M (down from $7.9M).
- Cash, equivalents, and investments $172.8M as of June 30, 2026; runway at least through 2027.
- Lead ABC-enabled anti-Aβ antibody AL137 selected; IND submission targeted Q1 2027 with first-in-human dosing in Australia by April 2027.
- Tau siRNA program AL064/AL164 advancing into IND-enabling studies; AL050 GCase ERT for PD in preclinical development.
- R&D expenses fell to $19.5M from $27.6M; G&A expenses fell to $8.3M from $14.4M, driven by workforce reductions.

## SEC filing metadata
- accession: 0001193125-26-338008
- form_type: 8-K
- ticker: ALEC
- cik: 0001653087
- company_name: Alector, Inc.
- filed_at: 2026-08-06T20:10:49+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653087/000119312526338008/0001193125-26-338008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653087/000119312526338008/alec-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-338008
- JSON: https://secwatch.observer/filing/0001193125-26-338008.json
- Plain text: https://secwatch.observer/filing/0001193125-26-338008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.